Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Novel Immunotherapy Combinations in First-Line R/M PD-L1+ HNSCC
NCT06062420Phase 2Active, not recruiting
- Sponsor
- GSK
- Start
- Nov 2023
- Primary completion
- Sep 2026
- Modality
- Monoclonal Antibodies
- Countries
- 20
01
Overview
Phase 2, randomised, open-label trial of belrestotug, nelistotug and remzistotug in head and neck squamous cell carcinoma (HNSCC) (5 arms), sponsored by GSK. Primary endpoint: Confirmed Objective Response Rate at 24 months. Started Nov 2023; status: active, not recruiting.
02
Drugs
belrestotugnelistotugremzistotug
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT06062420.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06062420.